BCR-targeted therapies including ibrutinib (ibrutinib, a BTK inhibitor) have generated remarkable responses in treating mature B-cell malignancies including CLL[1–5]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.